Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells
- PMID: 11590434
- DOI: 10.1038/nm1001-1118
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells
Abstract
Despite the existence of tumor-specific antigens and demonstrated presence of tumor-specific immune cells, the majority of tumors manage to avoid immune-mediated destruction. Various mechanisms have been suggested for tumor evasion from immune response. One such mechanism is thought to be mediated by transforming growth factor-beta (TGF-beta), an immunosuppressive cytokine found at the site of most tumors. We demonstrate here that T-cell-specific blockade of TGF-beta signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells. In addition, we provide mechanisms through which abrogation of TGF-beta signaling leads to the enhancement of anti-tumor immunity. Our data indicate that T-cell-specific blockade of TGF-beta signaling has strong therapeutic potential to shift the balance of the immune response in favor of anti-tumor immunity.
Similar articles
-
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.Clin Cancer Res. 2004 Sep 1;10(17):5907-18. doi: 10.1158/1078-0432.CCR-03-0611. Clin Cancer Res. 2004. PMID: 15355924
-
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.Cancer Res. 2005 Mar 1;65(5):1761-9. doi: 10.1158/0008-5472.CAN-04-3169. Cancer Res. 2005. PMID: 15753372
-
[Better tumor eradication in transgenic altered T-lymphocytes. Role of the TGF-beta signal transduction cascade].Hautarzt. 2001 Dec;52(12):1135-6. Hautarzt. 2001. PMID: 11910867 German. No abstract available.
-
Role of TGF-beta in immune-evasion of cancer.Microsc Res Tech. 2001 Feb 15;52(4):387-95. doi: 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W. Microsc Res Tech. 2001. PMID: 11170297 Review.
-
TGF-β: guardian of T cell function.J Immunol. 2013 Oct 15;191(8):3973-9. doi: 10.4049/jimmunol.1301843. J Immunol. 2013. PMID: 24098055 Free PMC article. Review.
Cited by
-
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Int Rev Immunol. 2012 Feb;31(1):3-21. doi: 10.3109/08830185.2011.637254. Int Rev Immunol. 2012. PMID: 22251005 Free PMC article. Review.
-
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.Gene Ther. 2013 May;20(5):575-80. doi: 10.1038/gt.2012.75. Epub 2012 Sep 13. Gene Ther. 2013. PMID: 22972494 Free PMC article.
-
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.Nat Mater. 2012 Oct;11(10):895-905. doi: 10.1038/nmat3355. Epub 2012 Jul 15. Nat Mater. 2012. PMID: 22797827 Free PMC article.
-
MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model.Hum Vaccin Immunother. 2015;11(8):2012-20. doi: 10.1080/21645515.2015.1016669. Hum Vaccin Immunother. 2015. PMID: 25902414 Free PMC article.
-
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.Front Immunol. 2019 Nov 15;10:2689. doi: 10.3389/fimmu.2019.02689. eCollection 2019. Front Immunol. 2019. PMID: 31803194 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
